The feedback from the AAO meeting on the study design incorporating retreatment with aflibercept was positive. The flexibility was well-received, aligning with physician needs.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ...
